相关实验视频
Updated: Feb 6, 2026

08:15
Polymeric Microneedle Array Fabrication by Photolithography
Published on: November 17, 2015
13.0K
新型刺针微针阵列介导的双药物输送用于厚型婴儿血管瘤
Pei Wang1, Shih-Jen Chang1, Yajing Qiu1
1Department of Plastic and Reconstructive Surgery, Shanghai Key Laboratory of Tissue Engineering, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Advanced healthcare materials
|February 5, 2026
概括
一个新的微针系统为婴儿血管瘤 (IHs) 提供双重药物. 这种疗法有效地减少瘤体积并抑制IH的生长,提供了一个有前途的微创治疗选择.
科学领域:
- 生物材料科学 生物材料科学
- 皮肤病学 皮肤病学
- 纳米技术纳米技术
背景情况:
- 婴儿血瘤 (IHs) 引起并发症,特别是由于皮肤透不良而对局部蒂莫洛尔无反应的厚度病变.
- 用于IH的口服兰醇具有局限性,包括全身副作用和耐药性.
- 目前对内脏病的治疗需要更好的药物输送方法,以提高疗效和安全性.
研究的目的:
- 开发一种新的刺针微针 (MN) 系统,用于深度特定的双重药物输送,用于治疗婴儿血管瘤.
- 在协同疗法 (TM-BLM@MN) 中,将白素 (BLM) 用于深层切除和蒂莫洛尔 (TM) 用于表面血管收缩结合起来.
- 评估TM-BLM@MN系统在婴儿血瘤治疗中的体外和体内疗效.
主要方法:
- 开发一个有刺的微针 (MN) 系统,用于双药物输送白素 (BLM) 和蒂摩洛尔 (TM).
- 在体外评估TM-BLM@MN对血管瘤干细胞的增殖,迁移和管形成.
- 在体内评估TM-BLM@MN在减少婴儿血瘤瘤体积和病态血管生成方面的疗效.
主要成果:
- TM-BLM@MN在体外显示出大量抑制血管瘤干细胞的增殖,迁移和管形成.
- 与对照组相比,在体内使用TM-BLM@MN治疗导致瘤体积减少1.93倍.
- 组织学分析证实TM-BLM@MN显著抑制了婴儿血管瘤的病态血管生成.
结论:
- 新型刺针微针系统 (TM-BLM@MN) 为婴儿血管瘤提供了一个有效的深度特定的双重药物输送平台.
- 这种微创方法在治疗厚厚的IH病变方面表现出很高的疗效.
- TM-BLM@MN系统具有显著的临床转化潜力,并为IH患者提供了家庭治疗.
相关概念视频
Drug Delivery: Overview
879
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
879
Drug Delivery: Enteral Route
1.8K
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
1.8K
Drug Delivery: Parenteral Route
1.7K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
1.7K
Drug Delivery: Miscellaneous Routes
832
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
832
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
6.2K
Certain large, lipid-insoluble drug molecules that resemble amino acids, peptides, or glucose, require specialized carrier proteins to facilitate their diffusion across cell membranes. This transport can occur through either facilitated diffusion, which does not require energy input, or active transport, which does require energy input.
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
6.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
912
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
912

